# FXH holdings: all 72 positions

> All 72 FXH holdings with weights, as of Oct 13, 2026. The top 3 are CNC 2.65%, The Cigna Group 2.48% and ZBH 2.48%. Download the full list as a CSV.

Data as of Oct 13, 2026. Rebuilt every trading night.

FXH held 72 positions as of Oct 13, 2026. Centene Corporation is the largest at 2.65%; the top 10 are 24.4% of the fund.

Source: First Trust (https://www.ftportfolios.com/Retail/Etf/EtfHoldings.aspx?Ticker=FXH).

| # | Holding | Ticker | Weight |
| --- | --- | --- | --- |
| 1 | Centene Corporation | CNC | 2.65% |
| 2 | The Cigna Group | CI | 2.48% |
| 3 | Zimmer Biomet Holdings, Inc. | ZBH | 2.48% |
| 4 | Universal Health Services, Inc. (Class B) | UHS | 2.46% |
| 5 | Corcept Therapeutics Inc. | CORT | 2.44% |
| 6 | Globus Medical, Inc. (Class A) | GMED | 2.44% |
| 7 | Halozyme Therapeutics, Inc. | HALO | 2.37% |
| 8 | DexCom, Inc. | DXCM | 2.36% |
| 9 | Medpace Holdings, Inc. | MEDP | 2.34% |
| 10 | Solventum Corporation | SOLV | 2.34% |
| 11 | Caris Life Sciences, Inc. | CAI | 2.30% |
| 12 | Natera, Inc. | NTRA | 2.29% |
| 13 | Guardant Health, Inc. | GH | 2.17% |
| 14 | Medtronic Plc | MDT | 2.06% |
| 15 | Zoetis Inc. | ZTS | 2.03% |
| 16 | GE HealthCare Technologies Inc. | GEHC | 2.01% |
| 17 | Tenet Healthcare Corporation | THC | 2.00% |
| 18 | Tempus AI, Inc. (Class A) | TEM | 1.99% |
| 19 | Exelixis, Inc. | EXEL | 1.95% |
| 20 | Eli Lilly and Company | LLY | 1.93% |
| 21 | United Therapeutics Corporation | UTHR | 1.92% |
| 22 | Boston Scientific Corporation | BSX | 1.90% |
| 23 | Regeneron Pharmaceuticals, Inc. | REGN | 1.90% |
| 24 | Amgen Inc. | AMGN | 1.87% |
| 25 | The Cooper Companies, Inc. | COO | 1.85% |
| | US Dollar | | 0.10% |
| | Cash and other net assets | | 0.02% |

The largest 25 of 72 positions are shown. All of them: https://etfiq.com/funds/fxh/holdings/fxh-holdings.csv (CSV) or https://etfiq.com/data/books/fxh.json (JSON).

Fund page: https://etfiq.com/funds/fxh

Cite: ETFIQ, Holdings of FXH, data as of Oct 13, 2026. https://etfiq.com/funds/fxh/holdings/
